Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
enoxaparin sodium
Techdow Pharma Netherlands B.V.
B01AB05
enoxaparin sodium
Antithrombotic agents
Venous Thromboembolism
Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.
Revision: 25
Authorised
2016-09-15
320 B. PACKAGE LEAFLET 321 PACKAGE LEAFLET: INFORMATION FOR THE USER INHIXA 2,000 IU (20 MG)/0.2 ML SOLUTION FOR INJECTION INHIXA 4,000 IU (40 MG)/0.4 ML SOLUTION FOR INJECTION INHIXA 6,000 IU (60 MG)/0.6 ML SOLUTION FOR INJECTION INHIXA 8,000 IU (80 MG)/0.8 ML SOLUTION FOR INJECTION INHIXA 10,000 IU (100 MG)/1 ML SOLUTION FOR INJECTION enoxaparin sodium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Inhixa is and what it is used for 2. What you need to know before you use Inhixa 3. How to use Inhixa 4. Possible side effects 5. How to store Inhixa 6. Contents of the pack and other information 1. WHAT INHIXA IS AND WHAT IT IS USED FOR Inhixa contains the active substance called enoxaparin sodium that is a low molecular weight heparin (LMWH). Inhixa works in two ways: 1) Stopping existing blood clots from getting bigger. This helps your body to break them down and stop them causing you harm. 2) Stopping blood clots forming in your blood. Inhixa can be used to: Treat blood clots that are in your blood Stop blood clots from forming in your blood in the following situations: o Before and after an operation o When you have an acute illness and face period of limited mobility o If you have experienced a blood clot due to cancer to prevent further clots from forming. o When you have unstable angina (a condition when not enough blood gets to your heart) o After a heart attack Stop blood clots forming in the tubes of your dialysis machine (used for people with severe kidney probl Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10,000 IU/mL (100 mg/mL) solution for injection Each pre-filled syringe contains enoxaparin sodium 2,000 IU anti-Xa activity (equivalent to 20 mg) in 0.2 mL water for injections. For the full list of excipients, see section 6.1. Enoxaparin sodium is a biological substance obtained by alkaline depolymerisation of heparin benzyl ester derived from porcine intestinal mucosa. 3. PHARMACEUTICAL FORM Solution for injection in pre-filled syringe (injection). Clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Inhixa is indicated in adults for: _ _ Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery. Extended treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of its recurrence in patients with active cancer. Prevention of thrombus formation in extra corporeal circulation during haemodialysis. Acute coronary syndrome: Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Prophylaxis of venous thromboembolic disease in moderate and high risk s Przeczytaj cały dokument